The need for new antimicrobials for intra-abdominal infections (IAI): Defining the forthcoming scenario

Surgical Infections

Volumn 7, Issue 1, 2006, Pages 1-4

  Tellado, Jose M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CLINAFLOXACIN; CLINDAMYCIN; DESQUINOLONE DERIVATIVE; ERTAPENEM; GENTAMICIN; METICILLIN; NEW DRUG; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CLINICAL TRIAL; DRUG DOSE REGIMEN; EDITORIAL; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS; STREPTOCOCCUS;

ABDOMEN; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; SURGICAL WOUND INFECTION;

EID: 33645579599     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.7.1     Document Type: Editorial

References (26)

1. Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: Implications for the future. Clin Infect Dis 2004;38:127-186.
2. Norrby SR. Lack of development of new antimicrobial drugs: A potential serious threat to public health. Lancet Infect Dis 2005;5:115-119.
3. Clark NM, Patterson J, Lynch JP 3rd. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003;9:413-423.
4. Solomkin JS, Mazuski JE, Baron EJ, et al., for the Infectious Diseases Society of America. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37: 997-1005.
5. Christiansen KJ, Bell JM, Turnidge JD, Jones RN. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY Program, 1999 to 2001. Antimicrob Agents Chemother 2004;48:2049-2055.
6. Sharma R, Sharma CL, Kapoor B. Antibacterial resistance: Current problems and possible solutions. Indian J Med Sci 2005;59:120-129.
7. Singh AK, Sen MR, Anupurba S, Bhattacharya P. Antibiotic sensitivity pattern of the bacteria isolated from nosocomial infections in ICU. J Commun Dis 2002; 34:257-263.
8. Goossens H, and the MYSTIC Study Group (Europe). MYSTIC program: Summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001;4: 183-189.
9. Dzierzanowska-Fangrat K, Semczuk K, Lopaciuk U, et al. Antimicrobial susceptibility of aerobic microorganisms isolated from intraabdominal infections in pediatric patients in Poland. Med Sci Monit 2005;11: CR241-245.
10. Wang H, Chen M, and the China Nosocomial Pathogens Resistance Surveillance Study Group. Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002. Diagn Microbiol Infect Dis 2005;51:201-208.
11. Wilcox MH. The need for a new broad spectrum antibiotic class. Surg Infect 2006;7:1 (this issue).
12. Stelling JM, Travers K, Jones RN, et al. Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg Infect Dis 2005;11:873-882.
13. Hedberg M, Nord CE, for the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteriodes fragilis group isolates in Europe. Clin Microbiol Infect 2003;9: 475-488.
14. Aldridge KE, O'Brien M. In vitro susceptibilities of the Bacteroides fragilis group species: Change in isolation rates significantly affects overall susceptibility data. J Clin Microbiol 2002;40:4349-4352.
15. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-973.
16. Gladman MA, Knowles CH, Gladman LJ, et al. Intraoperative culture in appendicitis: Traditional practice challenged. Ann R Coll Surg Engl 2004;86:196-201.
17. Montravers P, Chalfine A, Gauzit R, et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 2004;239:409-416.
18. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect 2002;3:161-173.
19. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. Surg Infect 2002;3:175-233.
20. Solomkin JS, Hemsell DL, Sweet R, Tally F, Bartlett J. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15(Suppl 1):S33-S42.
21. Babinchak T, Ellis-Grosse E, Dartois N, et al., for the Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005;41(suppl 5):S354-S367.
22. Centers for Disease Control and Prevention. Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. Available at www.cdc.gov/drugresistance/healthcare/default.htm; accessed 22 September 2005.
23. Commission of the European Communities. Community strategy against antimicrobial resistance. Brussels 20.06.2001. COM 2001, p 333.
24. Masterton RG. A new understanding of antibiotic resistance of nosocomial infections 2: Lessons for the future. Br J Intens Care 2005;Summer:65-71.
25. Von Baum H, Lin D, Wendt C. Prevalence of colonisation with third-generation cephalosporin-resistant Enterobacteriaceae in ICU patients of Heidelberg University Hospitals. Clin Microbiol Infect 2004;10:436-440.
26. Dinubile MJ, Chow JW, Satishchandran V, et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother 2005;49: 3217-3221.